The human brain has no conventional lymph nodes, no obvious drainage pipes. For most of medical history, scientists assumed it simply recycled its own waste internally. That picture has been crumbling for a decade, and a study published in May 2025 in iScience adds a striking new crack: fluid appears to creep along the middle meningeal artery (MMA) in a slow, lymphatic-like pattern that looks nothing like normal blood flow, suggesting the brain may have yet another route for flushing molecular debris.
What the MRI scans actually showed
A team led by researchers in Japan performed dynamic contrast-enhanced MRI on five healthy volunteers, injecting a gadolinium-based contrast agent and tracking where it traveled over time. In the tissue surrounding the MMA, signal enhancement built gradually and peaked at roughly 90 minutes, far slower than the seconds-to-minutes kinetics typical of arterial blood flow. That sluggish pace is consistent with fluid seeping through nonvascular channels, the kind of movement seen in lymphatic drainage elsewhere in the body. The researchers backed up their imaging with ex vivo tissue analysis, confirming that the MMA-peripheral region contains structures capable of supporting this type of flow.
Five participants is a small number, and the authors are careful to frame the result as preliminary. But the finding does not exist in a vacuum. It lands on top of a decade of discoveries that have fundamentally changed how neuroscientists think about waste removal from the brain.
A decade of discoveries behind this finding
The modern story begins in 2012 and 2013, when Maiken Nedergaard’s lab at the University of Rochester described the “glymphatic” system: a network of perivascular channels through which cerebrospinal fluid (CSF) washes through brain tissue, carrying away metabolic waste, particularly during sleep. That work, published in Science Translational Medicine, reframed the brain as an organ with active plumbing rather than a sealed compartment.
Two years later, a 2015 paper in Nature by Antoine Louveau and colleagues identified functional lymphatic vessels lining the meninges of mice, complete with the molecular markers expected of true lymphatic tissue. In 2017, a Nature Medicine study led by Martina Absinta confirmed that meningeal lymphatic vessels also exist in humans and nonhuman primates and can be visualized in living subjects using MRI with gadobutrol contrast and blood-vessel suppression. An NIH Research Matters summary of that work explained the mechanism: gadobutrol leaks from blood plasma into surrounding tissue, where lymphatic channels slowly collect it, producing a visible signal distinct from blood vessels.
Subsequent studies expanded the map. A 2019 Nature paper demonstrated that meningeal lymphatics at the base of the skull drain CSF in animal models, showing that drainage is not limited to the dorsal sinuses at the top of the head. And a 2018 Nature study tied the system directly to disease: when meningeal lymphatic function was impaired in aging mice, amyloid-beta buildup worsened and cognitive performance declined, a finding with obvious implications for Alzheimer’s research.
The new iScience finding fits logically into this framework. The MMA runs along the lateral and ventral dura, precisely the kind of territory where skull-base and ventral drainage routes have already been documented in animals. Showing that fluid moves in a lymphatic-like pattern along this artery in living humans extends the map into new anatomical territory.
Why confirmation is still needed
A sample of five healthy adults cannot tell us how this pathway behaves across ages, sexes, or disease states. No larger cohort studies or institutional imaging datasets have yet validated the MMA-associated drainage pattern, and no tracer-injection studies in humans have directly confirmed that waste products travel this route. The researchers have not published data on whether the pathway changes in people with mild cognitive impairment or early Alzheimer’s disease, a critical question if the MMA route is to have clinical relevance.
A separate methodological debate adds a layer of caution. In 2022, a team reported in Nature Communications that meningeal lymphatic structures could be visualized without contrast using 3D T2-FLAIR MRI, including in ventral regions near cranial nerves. But a peer-reviewed Matters Arising critique in the same journal challenged that interpretation, arguing that bright FLAIR signals outside the brain could have non-lymphatic explanations and that labeling them as lymphatic without ruling out alternatives carries significant methodological risk. No published response from the original team has directly addressed those specific objections.
The iScience study used a different technique, dynamic contrast-enhanced MRI rather than non-contrast FLAIR, so the critique does not apply directly. Still, the broader question hangs over the entire field: how confidently can any MRI method distinguish true lymphatic flow from other tissue signals? Signal timing and spatial patterns can strongly suggest lymphatic behavior, but the imaging community has not yet converged on universally accepted criteria. Independent replication with larger samples, complementary tracer studies, or histological confirmation in human tissue will be needed before the “lymphatic-like” label can be upgraded to established anatomy.
What this could mean for Alzheimer’s research and beyond
The practical stakes are real but still conditional. Animal studies have demonstrated that when meningeal lymphatic drainage falters, amyloid-beta accumulates faster and cognitive decline accelerates. If the MMA-associated pathway turns out to be a genuine clearance route in humans, it could become a therapeutic target: a structure that clinicians might try to keep open or enhance in patients at risk for neurodegeneration. Potential approaches could include pharmacologic agents that promote lymphatic flow or mechanical interventions that modulate CSF dynamics, but none of these applications can be tested until larger human studies confirm the pathway exists, characterize how it changes with age and disease, and determine whether it can be safely manipulated.
There is also a conceptual shift at play. For most of the 20th century, textbooks described the brain as “immune-privileged” and largely self-contained. The discoveries of the past decade, from glymphatic flow to meningeal lymphatics to skull-base drainage channels, have replaced that picture with something far more dynamic: a brain embedded in a fluid and immune network that extends through the meninges, along arteries, and into cervical lymph nodes. The MMA finding, if it holds, adds another branch to that network.
For now, the result is best understood as an early, intriguing data point rather than a clinical breakthrough. The imaging is suggestive, the anatomical logic is sound, and the supporting literature is substantial. What is missing is scale: more participants, more disease contexts, and convergent evidence from multiple methods. As imaging technology improves and research groups align on standardized protocols, the field will be better positioned to determine which of these candidate pathways genuinely handle waste clearance and which reflect the limits of how we currently peer inside the living brain.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
